6,982 Shares in Stryker Co. (NYSE:SYK) Acquired by Union Bancaire Privee UBP SA

Union Bancaire Privee UBP SA purchased a new position in shares of Stryker Co. (NYSE:SYK) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 6,982 shares of the medical technology company’s stock, valued at approximately $2,563,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of SYK. Parnassus Investments LLC acquired a new position in Stryker during the 3rd quarter worth approximately $762,798,000. RTW Investments LP purchased a new stake in Stryker during the 3rd quarter worth approximately $143,392,000. State Street Corp increased its holdings in Stryker by 2.2% during the 3rd quarter. State Street Corp now owns 14,582,959 shares of the medical technology company’s stock worth $5,279,788,000 after purchasing an additional 316,404 shares during the last quarter. FMR LLC increased its holdings in Stryker by 3.0% during the 3rd quarter. FMR LLC now owns 7,306,994 shares of the medical technology company’s stock worth $2,639,725,000 after purchasing an additional 215,782 shares during the last quarter. Finally, Public Sector Pension Investment Board increased its holdings in Stryker by 1,552.7% during the 3rd quarter. Public Sector Pension Investment Board now owns 207,889 shares of the medical technology company’s stock worth $75,102,000 after purchasing an additional 195,310 shares during the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Price Performance

Shares of SYK opened at $382.59 on Monday. The company has a market cap of $145.99 billion, a P/E ratio of 49.30, a PEG ratio of 2.93 and a beta of 0.96. The stock has a fifty day moving average price of $378.07 and a 200 day moving average price of $369.34. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the prior year, the company posted $3.46 earnings per share. On average, research analysts forecast that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.88%. Stryker’s payout ratio is currently 43.30%.

Insider Buying and Selling

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research firms have issued reports on SYK. Needham & Company LLC restated a “buy” rating and set a $442.00 price objective on shares of Stryker in a report on Wednesday, January 29th. Wells Fargo & Company lifted their price objective on Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. Citigroup lifted their price objective on Stryker from $411.00 to $450.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Evercore ISI lifted their price objective on Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Finally, Robert W. Baird lifted their price objective on Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Five investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and a consensus target price of $422.15.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.